



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
C12P 19/44, 1/06 // (C12P 19/44
C12R 1:465)

A1

(11) International Publication Number: WO 93/03169

(43) International Publication Date: 18 February 1993 (18.02.93)

(21) International Application Number: PCT/US92/06500

(22) International Filing Date: 3 August 1992 (03.08.92)

(30) Priority data:
740,370 5 August 1991 (05.08.91) US

(71) Applicant: BIO-TECHNICAL RESOURCES [US/US];
1035 South 7th Street, Manitowoc, WI 54220 (US).

(72) Inventors: EISENSCHINK, Michael, Allen ; 1703 Cedar
Grove Drive, Manitowoc, WI 54220 (US). OLSON, Phil-
lip, Terry ; 3220 Waldo Boulevard, Manitowoc, WI
54220 (US).


(74) Agents: STEVENSON, Robert, S. et al.; E.I. du Pont de
Nemours and Company, Legal/Patent Records Center,
1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AU, BB, BG, BR, CA, CS, FI, HU, JP,
KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, Eu-
ropean patent (AT, BE, CH, DE, DK, ES, FR, GB, GR,
IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).

Published

With international search report.

(54) Title: A FERMENTATION PROCESS FOR PRODUCING NATAMYCIN



(57) Abstract

A natamycin producing *Streptomyces* species ferments to produce natamycin. A spore suspension of the *Streptomyces* species is propagated in a predetermined medium to obtain a quantity of *Streptomyces* cells. The *Streptomyces* cells ferment in a predetermined production medium having a controlled pH to produce a recoverable amount of natamycin.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain			US	United States of America

-1-

A FERMENTATION PROCESS FOR
PRODUCING NATAMYCIN

5

BACKGROUND OF THE INVENTION

The present invention relates to a process
for producing natamycin characterized by inoculum
10 preparation, inoculum propagation and fermentation in a
broth having a pH from about 5.0 through about 6.5.

Natamycin is a member of the polyene family
of antimycotics. The compound natamycin is a tetraene
with a molecular weight of about 666, empirical formula
15 corresponding generally to $C_{33}H_{47}NO_{13}$, and it contains
a glycosidically-linked carbohydrate moiety,
mycosamine. Natamycin has an isoelectric point of
about pH 6.5. The structure of natamycin exist
typically in two configurations: the enol-structure
20 and the keto-structure.

The production of natamycin has been known
for years. A conventional fermentation process for
producing natamycin is disclosed in American Cyanamid's
British Patent No. 846,933 (1960). The disclosure of
25 United Kingdom Patent No. 846,933 is hereby
incorporated by reference.

Despite the antibiotic and anti-fungal value
of natamycin, very little commercial use has been made
of this product. One major reason for the limited use
30 is the prohibitively high manufacturing cost of
natamycin.

It is an object of the present invention to
overcome the inefficiencies of conventional processes
and provide a process for producing natamycin in a
35 cost-effective manner by propagating and fermenting an
inoculum in predetermined media having a controlled pH.

-2-

SUMMARY OF THE INVENTION

The present invention relates to fermentation by an organism capable of producing natamycin. Particularly the present invention is directed to preparing (e.g., sporulation) and propagating an inoculum comprising a *Streptomyces* species that, during fermentation, produces natamycin. The *Streptomyces* species is exposed to a series of predetermined environments and/or mediums which improve the rate at which natamycin is produced. It has been found that an enhanced rate of natamycin fermentation and improved yields can be achieved by adding sufficient amounts of basic pH control agents to the fermentation medium which maintain the pH between about 5.0 and 6.5.

A suitable aqueous medium for inoculum propagation comprises:

- a) a protein nitrogen source in an amount of from about 2-16 g/l, normally about 8 g/l; and
- b) a metabolizable carbon source present in an amount which is sufficient to avoid total carbon depletion, usually 5-30 g/l of medium, and normally about 15 g/l.

A suitable aqueous medium used during fermentation to induce the inoculum to produce natamycin comprises:

- a) about 80-250 g/l of a metabolizable carbon source; and
- b) a protein nitrogen source containing a high level of protein and trace ingredients. The protein nitrogen source typically comprises a non-yeast protein nitrogen component and a yeast protein nitrogen component. These two protein nitrogen components are desirably present in a ratio ranging, respectively, from about 5:1 to 11:1

-3-

based on protein contents, and for best results generally about 8:1.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Fig. 1 is a schematic block diagram of the process which may be used in the invention for inoculum propagation.

 Fig. 2 is a graphical representation of the three phases which typically occur during fermentation.

10 Figure 3 is a graph of time vs. natamycin production for the natamycin produced in accordance with Tests 4 through 6 of the Example.

DETAILED DESCRIPTION OF THE INVENTION

15 In accordance with the present invention, an organism capable of producing natamycin is placed into contact with a predetermined medium to produce an inoculum, and then into a predetermined fermentation production medium that will support maximum metabolic
20 activity of the organism during further propagation and natamycin producing fermentation. During fermentation the organism transforms at least a portion of the predetermined production medium into natamycin. It has been found that an enhanced rate of natamycin
25 production and improved yields of natamycin can be achieved by adding sufficient amounts of basic pH control agents to the fermentation medium which maintain the pH between about 5.0 and about 6.5.

 Any organism which comprises a natamycin
30 producing *Streptomyces* species can be used in accordance with the invention. A preferred *Streptomyces* species comprises *Streptomyces gilvosporeus* which has been deposited previously with the American Type Culture Collection (ATCC) in Rockville, Maryland,
35 United States of America, and is registered as ATCC No. 13326.

-4-

An inoculum is prepared from a spore suspension of the appropriate spores. The inoculum of the appropriate *Streptomyces* species is subsequently fermented which produces high yields of natamycin when placed into the fermentation medium of the invention. The inoculum is typically exposed to a series of propagation steps wherein each step increases the quantity of the natamycin producing *Streptomyces* cells. After the quantity of *Streptomyces* cells is adequate, the *Streptomyces* is exposed to an environment and/or a medium which is designed to enhance natamycin production when the *Streptomyces* species ferments.

Spore Suspension

The inoculum is started by collecting the spores of a natamycin producing *Streptomyces* species which was obtained from the American Type Culture Collection. The spores are germinated to produce an actively growing culture of the *Streptomyces* species. A sterilized (e.g., autoclaved), agar slant is inoculated heavily with the actively growing culture of the *Streptomyces* species (e.g., *Streptomyces gilvosporeus* or any other natamycin producing species), and incubated until the slant is covered substantially entirely with spores. The spores on the agar slant are scraped into a small amount of a liquid, such as water (e.g., distilled water), nutrient medium, etc., to produce an aqueous spore suspension. The resulting spore suspension is propagated to produce the inoculum for the fermentation operation (i.e., natamycin production). For achieving the best results, the spore suspension used to begin inoculum propagation should contain a spore concentration of about 10^5 - 10^{10} CFU/ml, and, normally, at least about 10^8 CFU/ml.

A number of agar slant media can be used to promote sporulation of the culture of the *Streptomyces*

-5-

species (e.g., *S. gilvosporeus*), which will be used to form the spore suspension. Appropriate agar slant mediums typically comprise at least one member of the following group: yeast malt agar, Hickey-Turner agar, GYA agar, Pridham agar, potato dextrose, Bennett's agar, etc.

A high concentration (e.g., 10^8 CFU/ml), of viable spores within the spore suspension is a key aspect of the present invention. First, if the concentration of spores is too low, it takes much longer to obtain, through inoculum propagation, the quantity of *Streptomyces* cells sufficient for cost-effective natamycin fermentation production. Second, a reduced quantity of spores within the suspension lengthens the total inoculum propagation time and increases the likelihood of contamination (e.g., by an unwanted organism). Further, a low spore concentration within the suspension may tend to promote the formation of large, tightly packed mycelial pellets. These pellets are unsuitable for obtaining high yields of natamycin due to problems associated with oxygen transfer, mass transfer of nutrients into the pellets, etc. Should the size of mycelial pellets become undesirable, the pellets can be broken apart physically, such as by using a shear force (e.g., blending).

Inoculum Propagation

The aqueous spore suspension (e.g., *S. gilvosporeus*), discussed above, is germinated and cell multiplication continued until the number of organisms is adequate to be used as an aqueous inoculum for fermentation production of natamycin. A suitable inoculum cell density comprises a dry cell weight of about 1-5 g/l and is used at a volume of about 0.1-10% of the natamycin production medium volume.

-6-

The aqueous medium used for inoculum propagation determines the cell density and the metabolic state of the inoculum (e.g., an adequate density of healthy cells is desirable). A sufficient
5 amount of protein nitrogen, which contains complex growth factors (e.g., vitamins), and inorganic elements (e.g., potassium, sodium, calcium, etc.), and trace elements (e.g., boron, cobalt, iron, copper, zinc, etc.), that are commonly present in the protein
10 nitrogen source, are needed to achieve an inoculum possessing the desired cell density and metabolic state. The protein nitrogen source may be any source that will propagate the spore suspension into an inoculum that will produce the desired high yields of
15 natamycin.

A metabolizable source of carbon must also be supplied to the aqueous inoculum medium in an amount which is sufficient to achieve the desired inoculum cell density. For best results, the carbon source
20 should not be depleted completely during the inoculum propagation. Depletion of the carbon source tends to alter adversely the metabolic state of the inoculum, which may lead to reduced yields of natamycin during fermentation.

25 Although a variety of aqueous inoculum media can be used effectively in accordance with the present invention, to obtain high yields of natamycin it is advantageous to use predetermined amounts of medium ingredients.

30 A suitable medium for inoculum propagation may be prepared in water (e.g., low mineral content water, distilled water, etc.), and comprises:

- a) a protein nitrogen source in an amount from about 2-16 g/l, normally about 8 g/l; and
- 35 b) a metabolizable carbon source present in an amount which is sufficient to avoid total

-7-

carbon depletion, usually 5-30 g/l of medium, and normally about 15 g/l.

Two specific compositions of a medium appropriate for inoculum propagation are given below.

5	<u>Composition 1</u>	<u>Quantity</u>
	Difco "Bacto" peptone	5 g/l
	Corn steep liquor	3 "
	Sodium chloride	10 "
	Glucose	15 "
10	<u>Composition 2</u>	<u>Quantity</u>
	Hormel peptone PSR 5	8 g/l
	Sodium chloride	10 "
	Glucose	15 "

The inoculum medium which provides nutrients that enhances the production rate of *Streptomyces* cells may be prepared by conventional techniques(e.g., separate or simultaneous sterilization of the carbon and nitrogen sources at temperatures of about 120-140°C). The inoculum medium after sterilization, desirably has a pH of about 7. The spore suspension is introduced to the inoculum medium and the inoculum medium is heated to a temperature of about 25 - 40°C and, normally, about 28 - 35°C.

In order to achieve the large volumes of aqueous inoculum which are desirable for fermentation production of natamycin, several inoculum propagation steps are required, each carried out in a volume greater than the previous step. For example, the inoculum propagation may be conducted in a manner which achieves an exponential increase in the quantity of *Streptomyces* cells. Particularly, it is advantageous to keep the culture in an exponential growth mode during propagation by effectively increasing the volume of the inoculum during each step of the propagation. This can be done by either minimizing the duration of each step or by minimizing the number of steps. For

-8-

example, once a predetermined cell density of inoculum has been achieved, the inoculum is transferred to a larger environment (e.g., vessel), for further propagation. By effectively controlling the inoculum propagation a minimum of time and expense is devoted to inoculum propagation and, accordingly, cost-effective natamycin yields during fermentation are increased.

The length of time an individual step in the series of inoculum propagation steps is permitted to continue depends upon the composition of the medium, quantity of *Streptomyces* cells desired, temperature, etc. Typically, an individual propagation step is conducted for about 6 through at least about 24 hours.

The inoculum propagation process requires aeration of the inoculum. For example, the flask or vessel housing the inoculum may be agitated on a rotary shaker at about 200 rpm. In one aspect of the invention, the inoculum may be agitated by an impeller which is located within the vessel that houses the inoculum, while sterile air is forced into the bottom of the vessel.

Now referring to Fig. 1, this figure is a schematic of the process which may be used to produce the inoculum that is fermented to produce natamycin. Fig. 1 illustrates the volumetric increases in the inoculum which are typically achieved by propagation that are necessary to obtain a quantity of aqueous inoculum that is adequate to produce natamycin in a cost-effective manner. For example, the volume of inoculum is increased from 25 liters to 1250 liters by adding the 25 liters of inoculum to a vessel containing 1225 liters of an aqueous inoculum medium.

Natamycin Production

Natamycin production is conducted in a fermentation vessel which is capable of housing the

-9-

- fermentation process. It has been found that an enhanced rate of natamycin fermentation and improved yields can be achieved by adding sufficient amounts of basic pH control agents to the fermentation medium
- 5 which maintain the pH between about 5.0 and about 6.5. One aspect of the invention which is also important for achieving maximum yields of natamycin is the composition of the aqueous fermentation medium. The fermentation medium must contain the proper amounts of
- 10 metabolizable carbon and protein nitrogen. Also, it is desirable that the medium include complex growth factors (e.g., vitamins), inorganic elements (e.g., potassium, sodium, calcium, etc.), and trace elements (e.g., boron, cobalt, iron, copper, zinc, etc.)
- 15 A suitable medium for fermentation may be prepared in water(e.g., low mineral content water, distilled water, etc.), and comprises:
- a) about 80-250 g/l of a metabolizable carbon source; and
 - 20 b) at least about 15 g/l and, normally about 20 g/l through 80 g/l, of a protein nitrogen source containing a high level of protein and trace ingredients. The protein nitrogen source may comprise a non-yeast protein nitrogen component
 - 25 and a yeast protein nitrogen component. These two protein nitrogen components are usually present in the ratio ranging, respectively, from about 5:1 to 11:1 based on protein contents, and for best results generally about 8:1.
- 30 The protein nitrogen source may be supplied from a wide range of sources. For example, soy protein products may comprise the non-yeast protein nitrogen source (e.g., desirable natamycin yields are obtained with a soy protein source comprising 80-95% protein).
- 35 The protein nitrogen may also comprise beef extract and/or protein hydrolysates (e.g., peptones).

-10-

As discussed above, the production medium must also include a source of carbon which is metabolizable by the *Streptomyces* species. The carbon source may be supplied in any expedient form such as glucose, polysaccharide, corn and potato starches, etc.

Moreover, in one aspect of the invention, it is not necessary to initially introduce the entire quantity of the carbon source which is required to produce natamycin, as a starting component of the natamycin production medium (e.g., the initial quantity of the carbon source is not adequate for complete fermentation). In this aspect of the present invention, carbon source addition may be performed during the natamycin production so as to maintain a quantity of carbon source of about 5-30 g/l, and usually 20 g/l. Thus, an appropriate quantity of a suitable carbon source is added to the fermentation medium either initially and/or after the fermentation has begun. For example, the carbon source may be present in the fermentation medium in an amount of about 40-100 g/l. Thereafter, during the major period of fermentation, carbon source is continually added to the fermentor at a rate which is at least equivalent to the rate at which the carbon source is consumed enzymatically by the *Streptomyces* species during the fermentation process (e.g., to maintain the carbon source concentration at or above a minimum level). Toward the end of the fermentation process and after the major fermentation period, the carbon source addition is discontinued so that little or no carbon source is left at the end of the fermentation cycle (e.g., the quantity of the carbon source substantially equates to the particular quantity of carbon source within the fermentation medium which is necessary to complete the fermentation process).

-11-

The natamycin production medium, which provides nutrients for the *Streptomyces* fermentation and natamycin production may be prepared by conventional techniques (e.g., separate or simultaneous
5 sterilization of the carbon and nitrogen sources at temperatures of about 120-140°C). The production medium, after sterilization, desirably has a pH of about 7.

The inoculum is introduced until a
10 concentration of about 0.1-10%, usually about 2%, by volume is achieved in the production medium (e.g., the quantity of inoculum may be sufficient to inoculate a plurality of fermentors). The remainder of the volume of the fermentor comprises the fermentation medium
15 discussed above. Any technique is acceptable for introducing the inoculum to the production medium within the fermentor which delivers the inoculum in an active metabolic state.

The fermentation or production medium is
20 brought to a temperature of about 25°-40°C, and normally about 28°-35°C. The length of time which the fermentation process is allowed to continue depends upon the composition of the fermentation medium, temperature, quantity of *Streptomyces* cells in the
25 inoculum, quantity of natamycin desired, etc. Typically, the fermentation process is conducted for about 70 through at least about 168 hours.

Oxygen is supplied to the natamycin production medium during fermentation. It is
30 advantageous to maintain a dissolved oxygen level in the production medium of about 20%-80% of air saturation during the major portion of the fermentation. The ability to achieve a suitable dissolved oxygen level may be enhanced by proper
35 adjustment of the aeration and/or agitation rate. For example, the fermentation or production medium must be

-12-

aerated by forcing air (e.g., sterile air), through the fermentation medium, usually at a rate of about 0.3 through at least about 1.0 volumes of air per volume of fermentation medium. In one aspect of the invention it is desirable to agitate the fermentation medium while being aerated. Further, the rate of aeration may be sufficient to cause agitation of the fermentation medium.

Referring now to Fig. 2, the relationship between time and natamycin production rates is shown for each of the three phases of the process. The first phase includes addition of the carbon source to the fermentation medium and growth or multiplication of the *Streptomyces* species. The first phase is also accompanied by natamycin production. The concentration of natamycin in the fermentation broth increases as the propagation of the cells of the *Streptomyces* species increases. The increase in the concentration of natamycin increases generally exponentially with time during the first phase. Eventually, the concentration of natamycin will increase constantly with time, which indicates that the second phase (i.e., the major phase) of natamycin production has been achieved. The third phase is characterized by a plateau in the concentration of natamycin (e.g., which may be due to a slowing of the metabolic activities of the *Streptomyces* species). The concentration of natamycin within the fermenter may be analyzed with respect to time in order to ascertain the current phase of fermentation. It is desirable to use a medium and/or an environment which induces the second phase of fermentation to be reached rapidly and maintained in order to maximize the overall quantity of natamycin that is produced.

In one aspect of the invention, it may be desirable to add an anti-foaming agent (e.g. silicone defoamer), to the fermentation medium in an amount of

-13-

from about 0.01%-1% by volume of the fermentation or natamycin production medium when it is desirable to control foaming.

The natamycin production medium after
5 inoculum addition has a pH of about 7. As discussed above, during the relatively short first phase of fermentation, rapid culture propagation is the major activity. Thereafter natamycin production becomes the predominant activity, and the pH drops. Controlling or
10 maintaining the pH during fermentation is a key aspect of the invention because, without pH control, the pH will drop to about pH 4.0 during natamycin production.

The major or second phase of natamycin production corresponds to the period beginning when the
15 pH has first dropped below about pH 6.5 until near the end of the natamycin production. Toward the end of the fermentation the pH may be allowed to drop below about pH 5.0. In accordance with the invention, the major phase does not include this low pH period when the pH
20 is below about pH 5.0.

The pH of the fermentation broth which comprises the fermentation medium may be controlled by adding pH control agents to the broth. The pH control agents used in the process of the invention comprise
25 hydroxides and basic salts that will control the pH without adversely affecting the natamycin production and recovery. Suitable pH control agents comprise at least one of sodium potassium and calcium hydroxides, and mono-, di- and trisodium and potassium citrates,
30 etc.

In accordance with the invention, the pH of the fermentation cycle is allowed to drop initially, (i.e., during culture propagation), to about pH 6. By this time effective natamycin production is underway.
35 After the pH has dropped into the range of from about pH 5.0 to about 6.5, addition of the basic pH control

-14-

agent is commenced and continued at rates sufficient to maintain the fermentation broth thereafter at a pH of about 5.0 through about 6.5. Normally, the pH is maintained by automatic pH controlled titration with an aqueous solution including the pH control agent.

A variety of pH control agent compositions, blends, mixtures, etc., can be used simultaneously and/or sequentially. For example, it may be desirable to introduce both a citrate salt and a hydroxide into the fermentation broth (e.g., a hydroxide could be added simultaneously to more easily maintain a pH of about 5.0-6.5). However, in some aspects of the invention, an acidic citrate can be added in conjunction with a basic pH control agent.

A key aspect of the invention comprises using a pH control agent comprising an inorganic base to maintain a pH of about 5.9-6.1. As aforementioned, the pH control of the present invention enhances the rate of natamycin production and improves the yield of natamycin. For example, the pH control of the invention may permit fermentation production of natamycin in far less time in comparison to an equivalent yield of natamycin produced without pH control. Typically, the production time is decreased 20-60%, with a reduction of about 35% being common.

When the present invention is practiced appropriately (e.g., effective handling of the *Streptomyces* inoculum, selection of media, etc.), the resultant fermentation broth will normally include at least about 5 g/l of natamycin. In certain cases, the level of natamycin production may range from about 7 g/l through at least about 12 g/l.

The natamycin can be separated from the production medium. In certain cases, the natamycin may be extracted from the fermentation broth and crystallized. Examples of acceptable techniques for

-15-

obtaining crystalline natamycin can be found in U.K. Patent No. 846,933.

The invention is demonstrated by the following Example which is intended to illustrate, not
5 limit, the scope of contemplated equivalents. Unless specified otherwise, commercially available reagent grade materials were used to conduct the following Example.

10 EXAMPLE

In the following tests, agar slants of the following compositions are prepared using distilled water.

3 g/l yeast extract (Difco "Bacto" Yeast
15 Extract)

3 g/l malt extract (Difco Malt Extract)

5 g/l peptone (Difco "Bacto" peptone)

10 g/l glucose

15 g/l agar.

20 The agar was sterilized at about 121°C for about 15 minutes.

An inoculum medium of the following composition was prepared in distilled water, and the pH was adjusted to about 7.0 with potassium hydroxide.

25 20 g/l glucose

10 g/l sodium chloride

6 g/l corn steep liquor (PPM (brand), Corn Steep Liquid)

6 g/l peptone (Difco "Bacto" peptone)

30 The inoculum medium was sterilized at about 121°C for about 15 minutes.

Streptomyces gilvosporeus, American Type Culture Collection Registration No. 13326, was obtained from the American Type Culture Collection as a freeze-
35 dried spore suspension and used as the culture source.

-16-

The culture was held on the agar slants at about 25°C until the culture sporulated.

The agar slants sporulated heavily within about 10 days and were used after 10-20 days. Spores
5 were scraped off these agar slants into the inoculum medium to achieve a spore suspension concentration of about 10^8 CFU/ml. About 2 ml of the spore suspension was added to about 100 ml of the inoculum medium in a 500 ml baffled flask. The inoculum in the baffled
10 flask was incubated for about 48 hours at about 29°C and agitated at about 200 rpm on a rotary shaker. After about 48 hours about 4 ml of this culture was added to about 200 ml of inoculum medium in a 1000 ml baffled flask, to propagate the inoculum. This
15 inoculum was then incubated for about an additional 24 hours at about 29°C and agitated at about 200 rpm on a rotary shaker. The inoculum thus produced was used to inoculate 8 l of production medium.

The natamycin production medium used in this
20 Example was of the following initial composition:

- 19.5 g/l soy protein isolate (ADM, "Profam" S970)
- 4.5 g/l yeast extract (Stauffer, Type KAT)
- 0.2 ml defoamer (Mazu, DF 289)

The production medium was prepared in distilled water
25 in a 14.0 l fermenter and the pH was adjusted to about 7.6 with potassium hydroxide. The fermenter was then sterilized for about 15 minutes at about 121°C. Glucose was sterilized separately as a 50% solution in distilled water.

30 Before inoculation, the production medium was heated to about 29°C and the glucose was added to achieve an initial concentration of glucose of about 40 g/l. An aeration rate of about 0.3 v/v-min. (volumes of air per volume of medium per minute) and an
35 agitation rate of about 300 rpm was established for the fermentor.

-17-

The inoculum discussed above containing *Streptomyces gilvosporeus*, (ATCC Registration No. 13326), was added to the fermentation vessel until the fermentation vessel had an inoculum content of about 2% by volume. Glucose was added to the inoculum after about 40 hours of fermentation in order to maintain a glucose concentration of about 20 g/l glucose in the fermentation vessel. This was done by feeding glucose to the fermenting vessel at a rate of about 1 g/l-hr. The agitation rate of the fermentation vessel was increased as necessary to maintain a dissolved oxygen level of about 50% of air saturation.

Test #1 - This test shows the typical practice of the high yield fermentation process, but without the pH control of the present invention. Proceeding as described above, starting with an initial volume of about 8.0 l production medium (pH of about 7) and continuing the fermentation cycle time for about 117 hours (pH of about 4.5), with a total glucose addition of about 110 g/l, a yield of about 7.3 g/l natamycin in about 8.7 l of fermentation broth was obtained (64 g natamycin, total).

Test #2 - Proceeding substantially as in Test #1, but after 18 hours when pH had dropped to about 6.0 adding about 20% KOH to maintain the pH at about 6.0, and adding about 155 g/l glucose over the cycle of about 92 hours there is obtained a natamycin yield of about 7.4 g/l in about 10.1 l (75 g natamycin, total). Thus, as compared to Test #1, this test of the present invention provides an equivalent yield of natamycin in a shorter production period.

By following substantially the same procedure but using NaOH instead of KOH, similar rapid high yield natamycin production was achieved.

-18-

Test #3 - Continuing production of Test #2 and adding about 250 g/l glucose over about a 282 hour total fermentation cycle time there was obtained a natamycin yield of about 12.4 g/l in about 10.4 l of fermentation broth (129 g natamycin, total). Thus, prolonged natamycin production is possible to give high natamycin yields.

Test #4 - Proceeding as in Test #2, but when the pH decreased to about pH 6, about 20% potassium hydroxide was added by automatic titration to maintain a pH of about 6.1-5.9. After about 66 hours fermentation time, about 6.6 g/l of natamycin was produced in about 9.2 l fermentation broth (61 g natamycin, total).

Test #5 - Proceeding as in Test #2, but at about 24 hours when the fermentation broth was at a pH of about 5.1, about 7 g/l of trisodium citrate was added to the fermentation vessel. The pH remained in a pH range from about 5.0 to 6.5. Fermentation was continued for about 69 hours. Production of natamycin was about 6.6 g/l in about 8.7 l (57 g natamycin, total).

By following substantially the same procedure but using an equimolar amount of tripotassium citrate, similar rapid high yield natamycin production was achieved.

Test #6 - By proceeding substantially in accordance with Test #5 except that in place of the trisodium citrate pH control agent, there was added at about 24 hours after the start of fermentation trisodium citrate adjusted to a pH of about 5.0 with citric acid (this addition contained about 5 g/l of citrate ion); then after about 45 hours citric acid was added to maintain pH below about 5.0. Only about 25.6 g of natamycin was produced after about 117 hours of fermentation.

-19-

Test #7 - Proceeding substantially in accordance with Test #1 but without the addition of any pH control agent, after about 66 hours of fermentation the natamycin yield was only 4.3 g/l in about 8.3 l
 5 broth (36 g natamycin, total). A comparison of Test #4 and Test #7 illustrates that pH control will enhance the natamycin production rate (i.e., the 66 hour fermentation process of Test #4 produced 61 g of natamycin whereas Test #7 produced only 36 g of
 10 natamycin).

The following Table summarizes the results of Tests 1-7 in terms of relative speed of natamycin production. A review of the following Table demonstrates that the pH control of the invention
 15 improves the yield of natamycin obtained via a fermentation process.

TABLE

20	<u>Test #</u>	<u>pH Control Agent</u>	<u>Production Time (hrs)</u>	Quantity
				<u>Natamycin Produced</u> (Total/Concentration)
	1	None	117	64 g/7.3 g/l
	2	KOH	92	75 g/7.4 g/l
	3	KOH	282	129 g/12.4 g/l
25	4	KOH	66	61 g/6.6 g/l
	5	Trisodium citrate	69	57 g/6.6 g/l
	6	Trisodium citrate/		
30		Citric Acid	117	25.6 g/3.2 g
	7	None	66	36 g/4.3 g/l

Now, refer to Fig. 3, which is a graph illustrating the natamycin production (g/l in the
 35 fermentation broth) over about 115 hours of the fermentation process which was performed in accordance

-20-

with Tests 4, 5, 6 and 7. A review of Figure 3 illustrates graphically that the pH control of the invention enhances the rate at which natamycin is produced.

- 5 Although a few embodiments of the invention have been described above in detail, those skilled in this art will readily appreciate that the present invention embraces many combinations and variations.

-21-

WHAT IS CLAIMED:

1. A process for preparing natamycin by fermentation comprising:

- 5 propagating a spore suspension comprising a *Streptomyces* species in a predetermined inoculum medium to obtain an inoculum;
introducing the inoculum to a predetermined fermentation medium;
10 allowing the inoculum to ferment and produce natamycin,
controlling the pH of the fermentation medium to range from about 5.0 through about 6.5, and;
recovering the natamycin.

15

2. The process of Claim 1 wherein said natamycin producing species comprises *Streptomyces gilvosporeus*, ATCC 13326.

20

3. The process of Claim 1 wherein said spore suspension contains a spore suspension of at least 10^5 - 10^{10} CFU/ml.

4. The process of any one of Claims 1, 2 or
25 3 wherein said fermentation medium contains non-yeast and yeast protein nitrogen components, said non-yeast and yeast components being present in the ratio ranging, respectively, from about 5:1 to 11:1 based on protein contents.

30

5. The process of any one of Claims 1, 2 or
3 wherein the inoculum medium comprises from about 2 through about 16 g/l of a protein nitrogen source and about 5 through 30 g/l of a carbon source.

35

-22-

6. The process of any one of Claims 1, 2 or 3 wherein the fermentation medium comprises from about 80 through about 250 g/l of a carbon source and nitrogen source; wherein the nitrogen source further
5 comprises a non-yeast component and a yeast component.

7. The process of Claim 6 wherein the ratio of non-yeast and yeast components of said protein nitrogen source ranges from about 5:1 through about
10 11:1, based on a protein content.

8. The process of Claim 7 wherein said non-yeast component of said protein nitrogen source comprises soy protein.
15

9. The process of any one of Claims 1, 2 or 3 wherein the concentration of carbon source in the fermentation medium is maintained at about 5-30 g/l during the major natamycin production period.
20

10. The process of any one of Claims 1, 2 or 3 wherein at least 7 g of natamycin is produced per liter of fermentation medium.

25 11. The process of any one of Claims 1, 2 or 3 wherein the propagation and fermentation are conducted at temperature of from about 25 to about 40 degrees C.

30 12. The process of any one of Claims 1, 2 and 3 wherein the fermentation is conducted for a period of time from about 70 through at least about 168 hours.

-23-

13. The process of any one of Claims 1, 2 or 3 further comprising aerating the inoculum during propagation and fermentation.

5 14. The process of any one of Claims 1, 2 or 3 further comprising aerating the inoculum during natamycin production.


10 15. The process of any one of Claims 1, 2 or 3 wherein the inoculum and fermentation media include a carbon source which comprises at least one member from the group consisting of glucose, saccharide and starch.

15 16. The process of any one of Claims 1, 2 or 3 wherein the inoculum and fermentation media include a protein nitrogen source which comprises at least one member from the group consisting of soy protein, yeast and protein hydrolysate.


20 17. The process of Claim 15 wherein the protein nitrogen source comprises a soy protein comprising at least one member from the group consisting of isolates, flours and meals.

25 18. The process of Claim 15 wherein the protein nitrogen source comprises a yeast comprising at least one member from the group consisting of whole yeast extracts and autolysates.

30 19. The process of any one of Claims 1, 2 or 3 further comprising using a pH control agent comprising at least one member of the group consisting of hydroxides and citrates.


1/3
FIG. 1

2/3



3/3

FIG. 3



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/06500

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁴ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : C 12 P 19/44, C 12 P 1/06, (C 12 P 19/44, C 12 R 1:465)		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁵	C 12 P	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁶		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁸		
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	GB, A, 846 933 (AMERICAN CYANAMID COMPANY) 07 September 1960 (07.09.60), see claims 1-3 (cited in the application). ---	1, 2, 11
A	US, A, 3 892 850 (STRUYK et al.) 01 July 1975 (01.07.75), see claims 2-4. ---	1, 2, 11
A	GB, A, 2 106 498 (ANTIBIOTICOS SA) 13 April 1983 (13.04.83), see abstract. -----	1, 2
¹⁰ Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
07 September 1992	21 SEP 1992	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	WOLF e.h.	

ANHANG

zum internationalen Recherchen-
bericht über die internationale
Patentanmeldung Nr.

ANNEX

to the International Search
Report to the International Patent
Application No.

ANNEXE

au rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/US 92/06500 SAE 63053

In diesem Anhang sind die Mitglieder
der Patentfamilien der im obenge-
nannten internationalen Recherchenbericht
angeführten Patentdokumente angegeben.
Diese Angaben dienen nur zur Unter-
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family
members relating to the patent documents
cited in the above-mentioned inter-
national search report. The Office is
in no way liable for these particulars
which are given merely for the purpose
of information.

La présente annexe indique les
membres de la famille de brevets
relatifs aux documents de brevets cités
dans le rapport de recherche inter-
national visée ci-dessus. Les renseigne-
ments fournis sont donnés à titre indica-
tif et n'engagent pas la responsabilité
de l'Office.

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
GB A 846933		keine - none - rien	
US A 3892850	01-07-75	keine - none - rien	
GB A 2106498		DE A1 3228306	10-11-83
		FR A1 2511034	11-02-83
		FR B1 2511034	26-07-85
		GB A1 2106498	13-04-83
		GB B2 2106498	30-01-85
		JP A2 58067189	21-04-83
		JP B4 1042274	11-09-89
		ES A1 504582	16-12-82
		ES A1 8301278	16-02-83
		ES A5 504582	28-12-82